Chronic Kidney Disease., Hypertension
Conditions
Keywords
Elderly, Early stage chronic kidney disease, Hypertension, Eplerenone
Brief summary
The purpose of this study is to determine whether eplerenone is effective in the treatment of blood pressure, heart function, renal function in elderly hypertensive stage1 (eGFR\>=90ml/min/1.73m2) and stage2 (eGFR 60-89ml/min/1.73m2) chronic kidney disease (CKD) patients.
Detailed description
Chronic kidney disease (CKD) was reported to be affecting 11% of the all population. This number is much higher in the elderly population and may be as high as 30%. CKD is an independent risk factor of cardiovascular disease (CVD). This is called Cardio-renal Continuum. The renin-angiotensin-aldosterone system (RAS) plays pivotal roles in both cardiovascular and renal functions. The increased oxidative stress by activated RAS on vascular endothelium is one of important factor to development of Cardio-renal Continuum. The blockade of RAS by angiotensin I converting enzyme inhibitors (ACEIs) and/or angiotensin receptor blockers (ARBs) has been reported to ameliorate the renal disease and CVD; however,they do not completely suppress RAS and may induce aldosterone breakthrough that plays important roles for the development of CVD. Eplerenone, a selective aldosterone blocker, is effective against essential hypertension; however, little is known about the effects of eplerenone on heart and kidney functions in elderly hypertensive CKD patients. In this study, we assessed the efficacy of eplerenone on heart and kidney functions in elderly hypertensive early stage (stage1 (eGFR\>=90ml/min/1.73m2) and stage2 (eGFR 60-89ml/min/1.73m2)) CKD patients.
Interventions
DRUGEplerenone
50mg/day for all as initial dose, 100mg/day for the patients that still show hypertension(above 140/90mmHg)after one month 150mg treatment,oral,on 6 months
Sponsors
Jichi Medical University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Clinical diagnosis of stage1(eGFR\>=90ml/min/1.73m2) and stage2 (eGFR 60- 89ml/min/1.73m2)chronic kidney disease * Clinical diagnosis of Hypertension (Blood pressure \>=140/90mmHg) * Elderly people(\>=65 years old)
Exclusion criteria
* The patients who are already taking eplerenone * Stage3(eGFR 30-60 ml/min/1.73m2),stage4(eGFR 15-30 ml/min/1.73m2)and stage5 (eGFR \<15 ml/min/1.73m2) CKD patients * The patients who are receiving hemodialysis or peritoneal dialysis * The patients who are taking itraconazole, ritonavir and nelfinavir * The patients who are taking potassium-sparing diuretics and potassium supplement * The patients who have hyperkalemia(\>=5.5mEq/ml) * Severe heart failure (\>=NYHA class III) * Insulin dependent diabetic mellitus or poor controlled insulin independent diabetic mellitus (\>=HbA1c 9.0&) * Severe liver dysfunction (five folds increased AST or ALT than standard values)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change of heart function confirmed by echocardiograph and plasma level of BNP | 6 months |
| The change of renal function confirmed by eGFR and proteinuria. | 6 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The change of blood pressure | 6 months | The change of systolic blood pressure and diastolic blood pressure |
| The change of oxidative stress markers confirmed by plasma level of 8-OHdG and d-ROM | 6 months | — |
Outcome results
None listed